Certaines complications peuvent être réversibles avec un traitement approprié.
RéversibilitéTraitement approprié
#3
Y a-t-il des risques de maladies associées ?
Oui, des maladies métaboliques peuvent être associées à des anomalies de SLC12A4.
Maladies métaboliquesAnomalies
#4
Les complications affectent-elles la qualité de vie ?
Oui, les complications peuvent significativement affecter la qualité de vie des patients.
Qualité de vieComplications
#5
Des soins palliatifs sont-ils nécessaires ?
Dans les cas graves, des soins palliatifs peuvent être envisagés pour le confort.
Soins palliatifsConfort
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour SLC12A4 ?
Les antécédents familiaux et certaines conditions génétiques augmentent le risque.
Antécédents familiauxConditions génétiques
#2
L'environnement influence-t-il SLC12A4 ?
Oui, des facteurs environnementaux peuvent influencer l'expression de SLC12A4.
Facteurs environnementauxExpression génétique
#3
Le mode de vie joue-t-il un rôle ?
Oui, un mode de vie malsain peut exacerber les problèmes liés à SLC12A4.
Mode de vieProblèmes de santé
#4
Les infections augmentent-elles le risque ?
Certaines infections peuvent aggraver les symptômes liés à SLC12A4.
InfectionsSymptômes
#5
L'âge est-il un facteur de risque ?
Oui, l'âge peut influencer la gravité des symptômes et des complications.
ÂgeGravité des symptômes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Membre-4 de la famille-12 des transporteurs de solutés : Questions médicales les plus fréquentes",
"headline": "Membre-4 de la famille-12 des transporteurs de solutés : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Membre-4 de la famille-12 des transporteurs de solutés : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-17",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Membre-4 de la famille-12 des transporteurs de solutés"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Symporteurs des ions sodium-potassium-chlorure",
"url": "https://questionsmedicales.fr/mesh/D028021",
"about": {
"@type": "MedicalCondition",
"name": "Symporteurs des ions sodium-potassium-chlorure",
"code": {
"@type": "MedicalCode",
"code": "D028021",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.585.937.875"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Membre-4 de la famille-12 des transporteurs de solutés",
"alternateName": "Solute Carrier Family 12, Member 4",
"code": {
"@type": "MedicalCode",
"code": "D064507",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Simon Franz Müller",
"url": "https://questionsmedicales.fr/author/Simon%20Franz%20M%C3%BCller",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Justus Liebig University Giessen, Schubertstr. 81, D-35392 Giessen, Germany."
}
},
{
"@type": "Person",
"name": "Joachim Geyer",
"url": "https://questionsmedicales.fr/author/Joachim%20Geyer",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Justus Liebig University Giessen, Schubertstr. 81, D-35392 Giessen, Germany."
}
},
{
"@type": "Person",
"name": "Nipaporn Deejai",
"url": "https://questionsmedicales.fr/author/Nipaporn%20Deejai",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular Medicine, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand."
}
},
{
"@type": "Person",
"name": "Choochai Nettuwakul",
"url": "https://questionsmedicales.fr/author/Choochai%20Nettuwakul",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular Medicine, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand."
}
},
{
"@type": "Person",
"name": "Nunghathai Sawasdee",
"url": "https://questionsmedicales.fr/author/Nunghathai%20Sawasdee",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular Medicine, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37162564",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00417-023-06083-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39014498",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-024-08334-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Design and Methodological Issues of Within-Person (Split-Body) Randomized Controlled Trials Evaluating a Topical Treatment: A Systematic Review.",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/36990057",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000530149"
}
},
{
"@type": "ScholarlyArticle",
"name": "Laser and light therapy combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials.",
"datePublished": "2023-02-17",
"url": "https://questionsmedicales.fr/article/36800063",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10103-023-03734-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosus: study protocol of a randomized controlled trial.",
"datePublished": "2023-05-05",
"url": "https://questionsmedicales.fr/article/37145134",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00404-023-07055-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de transport membranaire",
"item": "https://questionsmedicales.fr/mesh/D026901"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines transporteurs de solutés",
"item": "https://questionsmedicales.fr/mesh/D000070590"
},
{
"@type": "ListItem",
"position": 7,
"name": "Symporteurs des ions sodium-potassium-chlorure",
"item": "https://questionsmedicales.fr/mesh/D028021"
},
{
"@type": "ListItem",
"position": 8,
"name": "Membre-4 de la famille-12 des transporteurs de solutés",
"item": "https://questionsmedicales.fr/mesh/D064507"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Membre-4 de la famille-12 des transporteurs de solutés - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Membre-4 de la famille-12 des transporteurs de solutés",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Membre-4 de la famille-12 des transporteurs de solutés",
"description": "Comment diagnostiquer une dysfonction de SLC12A4 ?\nQuels tests sont utilisés pour évaluer SLC12A4 ?\nY a-t-il des marqueurs spécifiques pour SLC12A4 ?\nLes imageries médicales aident-elles au diagnostic ?\nLe diagnostic nécessite-t-il une biopsie ?",
"url": "https://questionsmedicales.fr/mesh/D064507?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Membre-4 de la famille-12 des transporteurs de solutés",
"description": "Quels sont les symptômes d'une anomalie de SLC12A4 ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes sont-ils toujours présents ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D064507?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Membre-4 de la famille-12 des transporteurs de solutés",
"description": "Comment prévenir les troubles liés à SLC12A4 ?\nY a-t-il des tests de dépistage recommandés ?\nLes conseils génétiques sont-ils utiles ?\nLes vaccinations influencent-elles SLC12A4 ?\nL'exercice physique aide-t-il à prévenir les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D064507?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Membre-4 de la famille-12 des transporteurs de solutés",
"description": "Quels traitements sont disponibles pour SLC12A4 ?\nLa thérapie génique est-elle une option ?\nLes changements alimentaires aident-ils ?\nDes traitements symptomatiques existent-ils ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D064507?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Membre-4 de la famille-12 des transporteurs de solutés",
"description": "Quelles complications peuvent survenir avec SLC12A4 ?\nLes complications sont-elles réversibles ?\nY a-t-il des risques de maladies associées ?\nLes complications affectent-elles la qualité de vie ?\nDes soins palliatifs sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D064507?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Membre-4 de la famille-12 des transporteurs de solutés",
"description": "Quels sont les facteurs de risque pour SLC12A4 ?\nL'environnement influence-t-il SLC12A4 ?\nLe mode de vie joue-t-il un rôle ?\nLes infections augmentent-elles le risque ?\nL'âge est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D064507?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de SLC12A4 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques et des analyses biochimiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer SLC12A4 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de transport ionique et des analyses de sang peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour SLC12A4 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de marqueurs spécifiques largement reconnus."
}
},
{
"@type": "Question",
"name": "Les imageries médicales aident-elles au diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les imageries peuvent aider à évaluer des anomalies, mais ne sont pas spécifiques."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il une biopsie ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie n'est généralement pas nécessaire pour diagnostiquer SLC12A4."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une anomalie de SLC12A4 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des déséquilibres électrolytiques et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent se manifester différemment selon l'âge et le développement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez les signes de déshydratation et de fatigue excessive."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une anomalie."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, les symptômes peuvent s'aggraver avec le temps."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés à SLC12A4 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et une hydratation adéquate peuvent aider à prévenir les troubles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent être recommandés pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider à évaluer le risque familial."
}
},
{
"@type": "Question",
"name": "Les vaccinations influencent-elles SLC12A4 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les vaccinations n'ont pas d'impact direct sur SLC12A4."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un exercice régulier peut contribuer à une meilleure santé globale, mais pas spécifique."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour SLC12A4 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments électrolytiques et des médicaments spécifiques."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore une option standard."
}
},
{
"@type": "Question",
"name": "Les changements alimentaires aident-ils ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un régime équilibré peut aider à gérer les déséquilibres électrolytiques."
}
},
{
"@type": "Question",
"name": "Des traitements symptomatiques existent-ils ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements symptomatiques peuvent être prescrits pour soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des besoins individuels."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec SLC12A4 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des troubles rénaux et des déséquilibres électrolytiques graves."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies métaboliques peuvent être associées à des anomalies de SLC12A4."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Des soins palliatifs sont-ils nécessaires ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans les cas graves, des soins palliatifs peuvent être envisagés pour le confort."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour SLC12A4 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines conditions génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il SLC12A4 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux peuvent influencer l'expression de SLC12A4."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut exacerber les problèmes liés à SLC12A4."
}
},
{
"@type": "Question",
"name": "Les infections augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent aggraver les symptômes liés à SLC12A4."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut influencer la gravité des symptômes et des complications."
}
}
]
}
]
}
Diquafosol enhances fluid transfer and mucin secretion on ocular surface, which has been suggested as an effective treatment for dry eye disease (DED). The aim of the systematic review and meta-analys...
Relevant randomized controlled trials were obtained via search of electronic including PubMed, Embase, Cochrane Library, and Web of Science. A random-effects model was used to pool the results after i...
A total of nine RCTs involving 1295 patients with DED were included in the meta-analysis. Compared to treatment with 0.1% HA, topical treatment with 3% diquafosol significantly improved the Ocular Sur...
Topical treatment with 3% diquafosol may be more effective than 0.1% HA for patients with DED. However, the long-term efficacy and tolerability of diquafosol still need to be determined....
Narrowband ultraviolet B (NB-UVB) phototherapy is commonly prescribed for patients with moderate-to-severe atopic eczema (AE). The efficacy of NB-UVB, however, has not yet properly been established, a...
A pragmatic, multicenter, PROBE trial will be performed with 1:1 randomization of 316 adult patients with moderate-to-severe AE who have inadequate disease control with topical therapy and who are eli...
The UPDATE trial aims to provide high-quality evidence regarding the (cost-)effectiveness and safety of NB-UVB phototherapy in moderate-to-severe AE patients. Challenges that are addressed in the prot...
ClinicalTrials.gov NCT05704205. Registered on December 8, 2022....
Topical drugs are often used as first-line treatment for dermatological conditions. A within-person design may then be well adapted: it consists of randomizing lesions/body sites rather than patients,...
The aim of this review was to provide a methodological overview of within-person randomized trials (WP-RCTs) in dermatology....
We searched for eligible trials published between 2017 and 2021 in MEDLINE, Embase, and Central in dermatology journals and the 6 highest-impact-factor general medical journals. Two authors selected p...
From 1,034 articles identified, we included 54 WP-RCTs, mainly for acne vulgaris, psoriasis, actinic keratosis, and atopic dermatitis. In most of the trials, patients had only 2 lesions/body sites. In...
Our systematic review highlights that despite the publication of the CONSORT checklist extension for WP-RCTs in 2017, this design is rarely used, and when it is, there are methodological and reporting...
We aim to evaluate the clinical efficacy and safety of using laser and light combined with topical minoxidil for alopecia areata. We searched PubMed, Embase, Web of Science, the Cochrane Library, Chin...
Vulvar lichen sclerosus (LS) is a chronic debilitating inflammatory skin disease. Today, the gold standard is a life-long topical steroid treatment. Alternative options are highly desired. We present ...
We recruited 66 patients, 44 in the laser arm and 22 in the steroid arm. Patients with a physician-administered clinical LS score ≥ 4 were included. Participants received either four laser treatments ...
The findings of this trial have the potential to offer a novel treatment option for LS. The standardized Nd:YAG/Er:YAG laser settings and the treatment regime are presented in this paper....
NCT03926299....
Alopecia areata (AA) is a common autoimmune skin disease. Our study aimed to systematically evaluate the efficacy and safety of compound glycyrrhizin (CG) combined with topical minoxidil therapy in tr...
We searched the PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, Wanfang, and VIP databases. Randomized controlled trials (RCTs) on CG combined with topical minoxidil therapy compared with topi...
11 RCTs and 1189 patients were included. Compared with topical minoxidil therapy alone, CG combined with topical minoxidil therapy was more effective at improving the clinical efficacy (RR = 1.36, 95%...
The current evidence indicates that CG combined with topical minoxidil therapy is effective and safe for AA. However, owing to the suboptimal quality of the included studies, more high-quality and lar...
The purpose was to identify and summarize the existing evidence on the efficacy and safety of the topical application of olive oil for preventing pressure ulcers (PUs). We included only randomized con...
To investigate the clinical efficacy and safety of topical difamilast in mild-to-moderate atopic dermatitis (AD)....
Only randomized controlled trials (RCTs) that compared topical difamilast with vehicle treatment for patients with AD were included. PubMed, Web of Science, Ovid Medline, Cochrane Library, ClinicalTri...
Five studies enrolling a total of 1009 patients with mild-to-moderate AD were identified. Compared with the topical vehicle, topical difamilast was associated with a significantly higher success rate ...
This meta-analysis suggests that topical difamilast is an effective and safe treatment for mild-to-moderate AD....
Melasma is a chronic relapsing skin condition. Laser therapy is a new advancement in treatment. Whether the topical application of tranexamic acid (TXA) increases the efficacy of laser therapy in mela...
Randomized controlled trials are used to estimate the causal effect of a treatment on a health outcome of interest in a patient population. Often the specified treatment in a randomized controlled tri...
We use causal reasoning to explain why randomized controlled trials of biomarker targets can arrive at conflicting or misleading conclusions. We describe four key threats to the validity of trials of ...
We illustrate these findings using evidence from 15 randomized controlled trials of blood pressure targets for management of hypertension. Randomized trials of blood pressure targets exhibit substanti...
Researchers should critically assess meta-analyses of trials of targets for variation in the types, distributions, and off-target effects of therapies studied. Trial investigators should release detai...